HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases

HnRNPM is an essential splicing factor and its expression is closely correlated with invasion and metastasis of tumor cells. The CD44 cell adhesion molecule is aberrantly expressed in many breast tumors and CD44 splice variants have been implicated in specific oncogenic signaling pathways. To investigate the clinical significance and biological function of hnRNPM, immunohistochemistry, quantitative, and semiquantitative polymerase chain reaction, lentiviral transfection system and transwell invasion assays were performed. We found that hnRNPM expression was significantly upregulated in breast cancer tissues compared with benign breast lesions. Although there was no significant correlation between hnRNPM and total CD44 protein or mRNA level, there was a negative correlation between hnRNPM and CD44v6. HnRNPM and CD44s expression showed positive correlation and in particular, they were dually expressed in breast cancer tissues. Interestingly, cancer stem cells marker, ALDH1+ phenotype was positively associated with overexpression of CD44s or hnRNPM and negatively related to CD44v6. Patients with high hnRNPM tended to have higher levels of CD44s, shorter overall survival (OS) and higher rates of lymph node metastases (LNM). Remarkably, Kaplan‐Meier and Cox regression analyses displayed that hnRNPM+ or CD44shigh was a poor prognostic factor for OS of patients with LNM. Upregulation of hnRNPM in MCF‐7 cells caused a significant increase in cell invasion, and this effect may occur through the regulation of CD44s expression. In conclusion, overexpression of hnRNPM promotes breast cancer aggressiveness by regulating the level of CD44s, indicates a poor prognosis for patients with LNM, and has potential as therapeutic targets.

[1]  E. Borrelli,et al.  Regulatory Roles of Heterogeneous Nuclear Ribonucleoprotein M and Nova-1 Protein in Alternative Splicing of Dopamine D2 Receptor Pre-mRNA* , 2011, The Journal of Biological Chemistry.

[2]  K. Friedrichs,et al.  CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. , 1995, Cancer research.

[3]  R. A. Forse,et al.  Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver , 2011, Clinical & Experimental Metastasis.

[4]  Q. Sun,et al.  Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse , 2013, Cancer Cell International.

[5]  P. Howe,et al.  Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles. , 2010, RNA.

[6]  G. Davidson,et al.  CD44 functions in Wnt signaling by regulating LRP6 localization and activation , 2014, Cell Death and Differentiation.

[7]  Darren R. Williams,et al.  CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. , 2015, Oncology reports.

[8]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[9]  M. Barbolina,et al.  Expression and Function of CD44 in Epithelial Ovarian Carcinoma , 2015, Biomolecules.

[10]  David M. Rocke,et al.  Expression of CD44s and CD44v6 in Lung Cancer and Their Correlation with Prognostic Factors , 2011, The International journal of biological markers.

[11]  C. Ghigna,et al.  EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression , 2017, Molecular Cancer.

[12]  Baocun Sun,et al.  OCT4 Expression and Vasculogenic Mimicry Formation Positively Correlate with Poor Prognosis in Human Breast Cancer , 2014, International journal of molecular sciences.

[13]  M. Ringnér,et al.  CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers , 2011, BMC Cancer.

[14]  E. Wardelmann,et al.  Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K). , 2017, Cancer letters.

[15]  Gang Zhang,et al.  PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases. , 2017, Human pathology.

[16]  Xiaowu Li,et al.  CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients , 2014, Diagnostic Pathology.

[17]  Y. Yen,et al.  Mechanistic Control of Carcinoembryonic Antigen-related Cell Adhesion Molecule-1 (CEACAM1) Splice Isoforms by the Heterogeneous Nuclear Ribonuclear Proteins hnRNP L, hnRNP A1, and hnRNP M* , 2011, The Journal of Biological Chemistry.

[18]  Xiaowei Liu,et al.  Identification of HnRNP M as a novel biomarker for colorectal carcinoma by quantitative proteomics. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[19]  Premkumar Vummidi Giridhar,et al.  CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches , 2013, Experimental biology and medicine.

[20]  Yen-Ju Chen,et al.  Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer , 2017, Cell Death & Disease.

[21]  Jia Fan,et al.  Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma , 2013, International journal of cancer.

[22]  Baocun Sun,et al.  USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry , 2015, Molecular Cancer Therapeutics.

[23]  H. Choy,et al.  hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7. , 2014, Biochimica et biophysica acta.

[24]  Darren R. Williams,et al.  hnRNP L inhibits CD44 V10 exon splicing through interacting with its upstream intron. , 2015, Biochimica et biophysica acta.

[25]  B. Lei,et al.  HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis , 2016, Oncotarget.

[26]  Baocun Sun,et al.  Doxycycline as an Inhibitor of the Epithelial-to-Mesenchymal Transition and Vasculogenic Mimicry in Hepatocellular Carcinoma , 2014, Molecular Cancer Therapeutics.

[27]  Angus I Lamond,et al.  Direct interaction between hnRNP‐M and CDC5L/PLRG1 proteins affects alternative splice site choice , 2010, EMBO reports.

[28]  Fabian Birzele,et al.  CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients , 2015, Clinical Cancer Research.

[29]  Chia-Hsin Chan,et al.  Tackling Cancer Stem Cells via Inhibition of EMT Transcription Factors , 2016, Stem cells international.

[30]  A. Ahmed.  HER2 expression is a strong independent predictor of nodal metastasis in breast cancer. , 2016, Journal of the Egyptian National Cancer Institute.

[31]  Y. Yu,et al.  Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Chonghui Cheng,et al.  Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing , 2014, Genes & development.

[33]  V. Timmerman,et al.  The hnRNP family: insights into their role in health and disease , 2016, Human Genetics.

[34]  Gen Sheng Wu,et al.  CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer , 2016, International journal of oncology.